Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell tags : Research save search
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Published: 2024-04-07 (Crawled : 00:00) - globenewswire.com
ITOS | $10.58 -3.73% -3.88% 150K
|
Health Technology
|
| O: -1.0%
H: 2.26%
C: -1.29%
eos-984 association cancer cell research preclinical for meeting
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
CRBU | $3.86 -3.02% -3.11% 1.1M
|
Health Technology
|
| O: 1.63%
H: 0.54%
C: -0.67%
cb-012 association cancer cell research preclinical meeting car-t
Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K
|
|
| O: 8.8%
H: 0.0%
C: -5.66%
therapeutics
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
Published: 2023-12-05 (Crawled : 12:30) - prnewswire.com
GDTC | $2.15 -2.04% 990
|
|
| O: 0.82%
H: 0.82%
C: -3.27%
cell research technology therapeutics
T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.
Published: 2023-11-06 (Crawled : 15:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.54%
H: 0.73%
C: 0.2%
t-cell research therapy market
Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
Published: 2023-10-31 (Crawled : 13:00) - prnewswire.com
COEP | $0.3271 -2.36% -2.42% 150K
|
|
| O: -1.12%
H: 0.0%
C: -8.71%
cd20 her2 tumor research therapeutics potential growth
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 3.36%
H: 3.25%
C: -6.5%
day cell city research
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Published: 2023-08-17 (Crawled : 15:00) - biospace.com/
MRKR | $4.425 5.42% 10K
|
Consumer Services
|
| O: -1.54%
H: 4.53%
C: -1.56%
institute cell research car-t technology therapeutics
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
Published: 2023-06-13 (Crawled : 12:20) - globenewswire.com
PBLA | News | $0.42 -6.31% 64K
|
Professional, Scientific, and T...
|
| O: 13.23%
H: 22.83%
C: -16.44%
metabolic cell research car-t agreement therapy
Soligenix Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-11 (Crawled : 12:00) - biospace.com/
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: 3.5%
H: 0.58%
C: -8.88%
fda t-cell review treatment meeting study
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
SNGX | $0.385 -3.75% -3.9% 490K
|
Health Technology
|
| O: 150.7%
H: 17.98%
C: -35.96%
t-cell positive treatment results study
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.34%
H: 0.6%
C: -2.47%
breyanzi approval one cell therapy
IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023
Published: 2023-04-24 (Crawled : 14:00) - biospace.com/
INAB | $1.03 -0.96% -0.97% 150K
|
|
| O: 140.95%
H: 56.12%
C: 18.58%
inb-100 leukemia
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
Published: 2023-04-18 (Crawled : 16:00) - biospace.com/
IMUN | $0.093 214.52% 1.8K
|
Manufacturing
| Email alert
Add to watchlist
association cancer cell research meeting therapeutics results platform
PhenomeX Launches the Opto® T Cell Profiling Workflow
Published: 2023-04-17 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
opto cell
Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-04-17 (Crawled : 07:00) - biospace.com/
CLLS | News | $2.53 -3.42% -3.55% 39K
|
Health Technology
|
| O: 0.0%
H: 1.47%
C: 0.0%
talen breast association cancer research preclinical meeting negative
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-16 (Crawled : 20:20) - globenewswire.com
AFMD | $4.91 -8.22% -8.96% 65K
|
Health Technology
|
| O: 4.71%
H: 5.81%
C: 2.93%
afm13 association cancer cell research meeting study
Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
Published: 2023-03-29 (Crawled : 13:00) - biospace.com/
TMO | News | $577.39 0.49% 0.0% 2M
|
Health Technology
|
| O: 0.93%
H: 0.22%
C: -0.75%
t-cell
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.